It appears that your browser may be outdated and performance may be limited. The My Study builder is best viewed with the latest internet browsers. However, if you’d prefer to use our standard form, you can access it below.

Go to Internet Explorer Quick Quote Form

Dismiss this message

Salivary Bioscience News

Salivary Uric Acid as a Potential Biomarker for Neurogenerative Disease

Uric Acid as a Potential Peripheral Biomarker for Disease Features in Huntington’s Patients

Corey- Bloom, et al. (2020) frontiers in Neuroscience

Oxidative stress has long been implicated in the pathophysiology and progression of Huntington’s disease (HD). Uric acid (UA) is a naturally occurring antioxidant that is present in the brain and periphery. Growing evidence has implicated UA as a molecular biomarker for several neurodegenerative diseases, most notably Parkinson’s disease (PD). In this study, we investigated UA levels in clinical samples from HD patients and normal controls (NCs) and assessed potential relationships between UA levels and disease and clinical data. UA levels were measured in plasma (n = 107) and saliva (n = 178) samples from premanifest (pre-HD) and manifest HD patients and control subjects. Gender effects of UA levels were observed in both biofluids, with male patients showing higher UA levels compared to female patients. Comparisons of UA levels across diagnostic groups, separated by gender, revealed that both plasma and salivary UA levels were significantly lower in female pre-HD and manifest HD patients compared to NCs. Salivary levels of UA were also significantly lower in male manifest HD patients versus controls, but not in plasma. Correlations of peripheral UA levels to clinical data also showed differences according to gender. In male HD patients, both plasma and salivary UA levels were significantly negatively correlated with total functional capacity (TFC), while positive correlations were observed with total motor score (TMS). Female HD patients showed a significant positive correlation between plasma UA levels and TMS, while salivary UA levels from female patients were significantly correlated to disease burden. Finally, in a separate cohort, we show that UA levels are decreased in postmortem prefrontal cortical samples (n = 20) from HD subjects compared to matched controls. These findings suggest that decreased levels of UA in the brains of HD patients can be reflected in peripheral fluids, with salivary measures of UA particularly offering significant promise as a potentially relevant, non-invasive biomarker of disease symptoms and burden. Our findings further highlight the impact of sexual dimorphism in HD pathophysiology.

View Abstract

Keywords: Salivary, uric acid, Huntington’s disease, neurodegenerative disease, peripheral fluids

*Note: Salimetrics provides this information for research use only (RUO). Information is not provided to promote off-label use of medical devices. Please consult the full-text article.

Contact: Salimetrics (USA)
View All International Distributors

How to Collect Saliva for COVID-19 Testing

Collecting a saliva sample for COVID-19 testing is simple and easy to do with our Saliva Collection Methods. Relax – that’s the first step! Then watch one of these video collection instructions prior to starting your collection:

Saliva Collection Aid – Standard, 48-Format
Saliva Collection Aid – Narrow, 96-Well Format
Oral Swab with Syringe for Onsite Testing
Oral Swab with Storage Tube for Lab Testing

CALL 800.790.2258
ASK AN EXPERT   REQUEST A QUOTE

X
COVID-19 Collection